Investor Update via Investor Meet Company.
The original release is unavailable here.
Earlier from Scancell
- Partnership with NHS Cancer Vaccine Launch Pad
- Scancell to present at 2025 AACR Annual Meeting
- Issue of share options
- Scancell presenting at AACR IO conference
- Interim Results
Later from Scancell
- Scancell initiates new arm in SCOPE Phase 2 study
- Share Option Exercise
- Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
- Strong Phase 2 data on iSCIB1+ in Melanoma
- Director/PDMR Shareholding
Follow Scancell into a list and get an email when it puts out news.
Follow Scancell